- Question from WRDS: I had breast cancer almost 4 years ago and have been on Arimidex for 3 1/2 years. I've developed osteoporosis due to Arimidex and Lupron injections for ovarian ablation. Has there been any research to prove the effectiveness of Evista to treat both the osteoporosis and to prevent a breast cancer recurrence in postmenopausal women who have completed the 5-year course of aromatase inhibitors?
- Answers - Generosa Grana, M.D., F.A.C.P There is no data on Evista in the setting of breast cancer. The only data that is available, as we discussed earlier, is in women with osteoporosis and women at increased risk of breast cancer. So it is speculation to suggest that, after 5 years of an aromatase inhibitor, Evista will give you benefit in terms of recurrence. It is a drug that can be used to treat osteoporosis, but we clearly have more effective drugs in that setting. So I tend to dissuade my patients from Evista after tamoxifen use or aromatase inhibitor use because of the lack of data.
The Ask-the-Expert Online Conference called Updates From the 2008 ASCO Annual Meeting featured Generosa Grana, M.D., F.A.C.P. and Carol Kaplan, M.D. answering your questions about the latest research advances on screening, treatment, side effects, and more.
Editor's Note: This conference took place in June 2008.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.